Work with thought leaders and academic experts in genetics clinical

Jeffrey Townsend is a Professor of Organismic and Evolutionary Biology at Yale University. He received his Ph.D. from Harvard University in 2002 and his Sc.B. from Brown University in 1994. He has been a teacher at St. Ann's School and an Assistant Professor at the University of Connecticut. He is currently the Elihu Professor of Biostatistics at Yale University.

Edoardo Airoldi is a Professor in the Department of Machine Learning at Temple University. He is also the Director of the Center for Machine Learning and Health. He is a world-renowned expert in the fields of machine learning and artificial intelligence, with a focus on applications to health. Airoldi is a member of the prestigious Association for the Advancement of Artificial Intelligence (AAAI) and the International Machine Learning Society (IMLS). He has published over 200 papers in leading journals and conferences, and his work has been covered by various media outlets including The New York Times, The Wall Street Journal, The Economist, and Wired.

8 years of science and engineering experience integrating multi-omics data to identify biomarkers for cancer studies. Seeking to apply data analytics expertise to develop new diagnosis and treatment strategies.

Luke Connelly is Professor of Health Economics at the Centre for the Business and Economics of Health. He also holds a Professorial appointment (part-time) at The University of Bologna, to which he was appointed in 2017 via the Italian “Direct Call” ([link](https://www.unibo.it/sitoweb/luke.connelly/en)) process. In 2019 he was appointed as Honorary Professor at The University of Sydney. His main interests are in health economics and insurance economics and the effects of institutions (including legal constructs) on incentives and behaviour. He has also worked in other fields of applied microeconomics, including education economics and transport economics. His publications include papers in *Review of Income and Wealth*, *Health Economics*, *Journal of Health Economics*, *Journal of Risk and Insurance*, *Geneva Papers on Risk and Insurance*, *Accident Analysis and Prevention*, *Journal of Law and Medicine*, *Journal of Clinical Epidemiology*, *European Journal of Health Economics*, *International Journal of Health Economics and Finance*, *Social Science and Medicine*, *Economic Papers*, *Economic Analysis and Policy*, *Journal of Transport Economics and Policy*, *Labour Economics*, *Economics and Human Biology* as well as in a range of clinical journals, including *Lancet*. Luke has served on a number of public committees including the Medical Services Advisory Committee (MSAC), which advises the Australian Minister for Health on the safety, efficacy, effectiveness, and cost-effectiveness of new and extant listings on Australia's Medicare Benefits Schedule. He has extensive service on other public committees and taskforces as well as extensive teaching and consulting engagements with industry. Over his career he has been a chief investigator on research grants and contracts totalling more than $67m. He is a member of the Editorial Boards of European Journal of Health Economics and the International Journal on Environmental Research and Public Health. He is a member of the International Health Economics Association's Arrow Awards Committee, which awards an annual prize in honour of Nobel Laureate Kenneth Arrow for the best paper in the field. He is currently Guest Editor (with Christophe Courbage) on a Special Issue of the Geneva Papers on Risk and Insurance on Insurance and Emerging Health Risks. His current research interests include health service innovations to improve the health of people with chronic kidney disease(CKD). Ongoing interests include the economics of disability and insurance, compensable injury compensation schemes, and the determinants of health. Luke enjoys and has considerable experience teaching economics and health economics at both the graduate and undergraduate levels. In 2014 he was awarded the School of Economics Distinguished Teaching Award for his teaching on UQ's Master of Health Economics Program. In July 2016 and July 2019 he also taught summer schools in Health Economics and the Economics of Insurance at The University of Lucerne, Switzerland. Over the past 10 years he has been a chief investigator on grants totalling more than $70m.

Throughout my training, I have been focused toward my ultimate goal of becoming a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions. My clinical research is centered on the development of novel agents in GI cancers, with particular interest in combinatorial approaches of epigenetic therapies and immunotherapies combinations. I ran the first phase II study of combination epigenetic therapy and immunotherapy in advanced pancreatic adenocarcinoma and cholangiocarcinoma, working with a collaborative team that incorporates leading experts in cancer immunology, epigenetics and drug development. I was awarded the 2018 ASCO Conquer Cancer Foundation Young Investigator Award for this project.  Together with Dr. Yarchoan, we are running a clinical trial of a novel neoantigen-specific vaccine in combination with immune checkpoint inhibitors for advanced fibrolamellar carcinoma (FLC) (NCT04248569). My laboratory focus has been on developing and validating a preclinical mouse model of FLC to investigate mechanisms underlying FLC pathogenesis, and will become a critical tool for investigating novel therapeutic strategies in FLC.